It’s official: Gilead’s Dan O’Day pulls the plug on the lion’s share of their filgotinib collaboration as the FDA erects a high safety barrier. What went wrong?

Five years after Gilead plunked down $725 million in cash to partner with Galapagos on filgotinib, new CEO Dan O’Day has opted to shelve the rheumatoid arthritis drug and all but a much smaller piece of the old development plan in the US. The big biotech said Tuesday afternoon that…

Click to view original post